| # | Name | Compound Key | Action Type | Relation | Activity Value | Units | Assay ID | Assay Description | Comment | Assay | Assay Organism | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. |  DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | Activity | = | 40 | % | ALA2076200 | inhibitor [40% of control] | % | Rattus norvegicus | ||
| 2. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | Efficacy | = | 84.9 | % | ALA3531879 | % | Homo sapiens | |||
| 3. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | EC50 | = | 3.2 | uM | ALA3531878 | 5.50 | nM | Homo sapiens | ||
| 4. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | EC50 | = | 63.1 | uM | ALA3531874 | 4.20 | nM | Rattus norvegicus | ||
| 5. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | EC50 | = | 0.004 | uM | ALA3531532 | 8.40 | nM | Homo sapiens | ||
| 6. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | Activity | 0 | ALA3531875 | Inactive | Homo sapiens | |||||
| 7. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | inhibition | = | -0.16 | % | ALA4513082 | % | Severe acute respiratory syndrome coronavirus 2 | |||
| 8. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | Inhibition | = | -15.222 | % | ALA4495582 | % | Severe acute respiratory syndrome coronavirus 2 | |||
| 9. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | inhibition | = | -0.16 | % | ALA4513082 | % | Severe acute respiratory syndrome coronavirus 2 | |||
| 10. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | inhibition | = | -6.82 | % | ALA4808150 | % | Homo sapiens | |||
| 11. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | inhibition | = | 10.59 | % | ALA4808149 | % | Homo sapiens | |||
| 12. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | Hit score | = | 0.071 | ALA4303810 | Severe acute respiratory syndrome coronavirus 2 | |||||
| 13. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | Inhibition | = | -6.01 | % | ALA4303805 | % | Severe acute respiratory syndrome coronavirus 2 | |||
| 14. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | AC50 | > | 30 | uM | ALA5291887 | Summarised AC50 (mean value for measurements with a relation sign "="; largest value for measurements with relation sign ">") | nM | Homo sapiens | ||
| 15. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | AC50 | > | 30 | uM | ALA5291761 | Summarised AC50 (mean value for measurements with a relation sign "="; largest value for measurements with relation sign ">") | nM | Homo sapiens | ||
| 16. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | AC50 | > | 30 | uM | ALA5291759 | Summarised AC50 (mean value for measurements with a relation sign "="; largest value for measurements with relation sign ">") | nM | Homo sapiens | ||
| 17. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | AC50 | = | 10.391 | uM | ALA5291730 | 4.98 | Summarised AC50 (mean value for measurements with a relation sign "="; largest value for measurements with relation sign ">") | nM | Homo sapiens | |
| 18. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | AC50 | > | 30 | uM | ALA5291857 | Summarised AC50 (mean value for measurements with a relation sign "="; largest value for measurements with relation sign ">") | nM | Homo sapiens | ||
| 19. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | AC50 | = | 17.816 | uM | ALA5291871 | 4.75 | Summarised AC50 (mean value for measurements with a relation sign "="; largest value for measurements with relation sign ">") | nM | Homo sapiens | |
| 20. | DL-threo-β-(3,4-Dihydroxyphenyl)serine | Droxydopa | AC50 | > | 30 | uM | ALA5291869 | Summarised AC50 (mean value for measurements with a relation sign "="; largest value for measurements with relation sign ">") | nM | Homo sapiens |
The page will load shortly, Thanks for your patience!